1
|
Tam CSL, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss B, Moreno C, Szafer‐Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Ghia P, Wierda WG. CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL). Hematol Oncol 2021. [DOI: 10.1002/hon.32_2879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- C. S. L Tam
- Peter MacCallum Cancer Center & St. Vincent's Hospital and the University of Melbourne Haematology and Disease Group, Melbourne VIC Australia
| | - J. N Allan
- Weill Cornell Medicine, Hematology/Oncology New York USA
| | - T Siddiqi
- City of Hope National Medical Center Hematology Duarte USA
| | - T. J Kipps
- UCSD Moores Cancer Center Chronic Lymphocytic Leukemia San Diego USA
| | - R Jacobs
- Levine Cancer Institute Hematology and Medical Oncology Charlotte USA
| | - S Opat
- Monash University, Clinical Haematology Clayton VIC Australia
| | - P. M Barr
- Wilmot Cancer Institute University of Rochester Medical Center Hematology/Oncology Rochester USA
| | - A Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda Haematology Milan Italy
| | - L Trentin
- Hematology and Clinical Immunology Unit Department of Medicine University of Padova, Hematology Padova Italy
| | - R Bannerji
- Rutgers Cancer Institute of New Jersey Hematology/Oncology New Brunswick USA
| | - S Jackson
- Middlemore Hospital, Haematology Auckland New Zealand
| | - B Kuss
- Flinders University and Medical Centre Haemotology and Molecular Genetics, Bedford Park SA Australia
| | - C Moreno
- Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Hematology Barcelona Spain
| | - E Szafer‐Glusman
- Pharmacyclics LLC, an AbbVie Company, Translational Medicine Sunnyvale USA
| | - K Russell
- Pharmacyclics LLC, an AbbVie Company, Clinical Program Development Sunnyvale USA
| | - C Zhou
- Pharmacyclics LLC, an AbbVie Company, Biostatistics Sunnyvale USA
| | - J Ninomoto
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - J. P Dean
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - P Ghia
- ivision of Experimental Oncology Università Vita‐Salute San Raffaele and IRCCS Ospedale San Raffaele, Experimental Oncology Milan Italy
| | - W. G Wierda
- University of Texas MD Anderson Cancer Center Leukemia Houston USA
| |
Collapse
|
2
|
Coutre SE, Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Dai S, Szoke A, Dean JP, Kipps TJ, Ghia P. FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2. Hematol Oncol 2021. [DOI: 10.1002/hon.48_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. E. Coutre
- Stanford Cancer Center, Stanford University School of Medicine, Stanford California USA
| | - P. M. Barr
- Wilmot Cancer Institute, University of Rochester Medical Center, Clinical Trials Office Rochester USA
| | - C. Owen
- Tom Baker Cancer Centre, University of Calgary, Medicine and Oncology Calgary Canada
| | - T. Robak
- Medical University of Lodz, Copernicus Memorial Hospital, Hematology Lodz Poland
| | - A. Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda, Hematology Milan Italy
| | - O. Bairey
- Rabin Medical Center, Life and Medicine Sciences Petah Tikva Israel
| | - J. A. Burger
- University of Texas MD Anderson Cancer Center, Leukemia Houston USA
| | - P. Hillmen
- The Leeds Teaching Hospitals, St. James Institute of Oncology, Oncology Leeds UK
| | - S. Devereux
- Kings College Hospital, NHS Foundation Trust, Lymphoma Biology London UK
| | - S. Grosicki
- School of Public Health, Silesian Medical University, Hematology and Cancer Prevention Katowice Poland
| | - H. McCarthy
- Royal Bournemouth General Hospital, Hematology Bournemouth UK
| | - J. Li
- Jiangsu Province Hospital, Hematology Nanjing China
| | - D. Simpson
- North Shore Hospital, Hematology Auckland New Zealand
| | - F. Offner
- Universitair Ziekenhuis Gent, Internal Medicine and Pediatrics Gent Belgium
| | - C. Moreno
- Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Hematology Barcelona Spain
| | - S. Dai
- Pharmacyclics LLC, an AbbVie Company, Biostatistics Sunnyvale USA
| | - A. Szoke
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - J. P. Dean
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - T. J. Kipps
- UCSD Moores Cancer Center, Blood Cancer Research Fund San Diego USA
| | - P. Ghia
- Università Vita‐Salute San Raffaele and IRCCS Ospedale San Raffaele, Medical Oncology Milan Italy
| |
Collapse
|
3
|
Dean JP, Montgomery RB, Wan J, Cohen P, Haugk K, Corman JM, Ellis WJ, Dalkin BL, Ludwig DL, Plymate SR. On-target activity of neoadjuvant cixutumumab and combined androgen deprivation therapy for high-risk prostate cancer: A phase II trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.153] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
153 Background: IMC-A12 (cixutumumab) is a fully human monoclonal antibody which targets the insulin-like growth factor receptor 1. Preclinical data suggests that the combination of androgen deprivation and IMC-A12 is much more effective than either treatment alone. This clinical trial tests the effectiveness of the combined treatment in a neoadjuvant fashion before radical prostatectomy. We have assayed serum samples from the first 18 patients to identify signs of on-target activity in this setting. Methods: Eligible men with high risk localized prostate cancer are defined by one of the following: Gleason score ≥ 8, PSA ≥ 20, Clinical Stage T2c-T3, or a risk for relapse exceeding 50% as defined by the Kattan nomogram. Men are treated for 3 months with goserelin, bicalutamide, and biweekly IMC-A12 infusions (10 mg/kg). The primary objective of the trial is to determine the rate of pathological complete response with an accrual goal of 28 men. Using samples from the first 18 patients on study, serum protein markers were assayed by ELISA and serum PSA and glucose levels were determined by clinical laboratory analysis. Results: Significant increases in c-peptide (1.7-fold, p<0.01), IGF-I (4.1-fold, p<0.01), IGF-II (1.32-fold, p<0.001), IGFBP-3 (1.9-fold, p<0.01), growth hormone (8-fold, p<0.01) were noted after initiation of ADT+IMC-A12, compared to pre-treatment levels. Non-significant increases of insulin (1.9-fold), IGFBP-1 (2-fold), and glucose (1.24-fold) levels were seen. Stratification of patients by nadir PSA levels correlated with residual tumor volume, likelihood of positive surgical margins and likelihood of lymph node metastases. Interestingly, patients with lower nadir PSA levels had smaller increases in c-peptide (50%, p<0.01), insulin (66%, p<0.02) and blood sugar (21%, P<0.01) compared to the patients with higher nadir PSA levels. Conclusions: Combined with ADT in the neoadjuvant setting, IMC-A12 effectively targets the IGF-1R axis in prostate cancer patients. Metabolic differences between patients may alter the efficacy of IMC-A12 in this setting. [Table: see text]
Collapse
Affiliation(s)
- J. P. Dean
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; University of California, Los Angeles, Los Angeles, CA; Veterans Administration Puget Sound Health Care System, Seattle, WA; Virginia Mason Medical Center, Seattle, WA; ImClone Systems, New York, NY
| | - R. B. Montgomery
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; University of California, Los Angeles, Los Angeles, CA; Veterans Administration Puget Sound Health Care System, Seattle, WA; Virginia Mason Medical Center, Seattle, WA; ImClone Systems, New York, NY
| | - J. Wan
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; University of California, Los Angeles, Los Angeles, CA; Veterans Administration Puget Sound Health Care System, Seattle, WA; Virginia Mason Medical Center, Seattle, WA; ImClone Systems, New York, NY
| | - P. Cohen
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; University of California, Los Angeles, Los Angeles, CA; Veterans Administration Puget Sound Health Care System, Seattle, WA; Virginia Mason Medical Center, Seattle, WA; ImClone Systems, New York, NY
| | - K. Haugk
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; University of California, Los Angeles, Los Angeles, CA; Veterans Administration Puget Sound Health Care System, Seattle, WA; Virginia Mason Medical Center, Seattle, WA; ImClone Systems, New York, NY
| | - J. M. Corman
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; University of California, Los Angeles, Los Angeles, CA; Veterans Administration Puget Sound Health Care System, Seattle, WA; Virginia Mason Medical Center, Seattle, WA; ImClone Systems, New York, NY
| | - W. J. Ellis
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; University of California, Los Angeles, Los Angeles, CA; Veterans Administration Puget Sound Health Care System, Seattle, WA; Virginia Mason Medical Center, Seattle, WA; ImClone Systems, New York, NY
| | - B. L. Dalkin
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; University of California, Los Angeles, Los Angeles, CA; Veterans Administration Puget Sound Health Care System, Seattle, WA; Virginia Mason Medical Center, Seattle, WA; ImClone Systems, New York, NY
| | - D. L. Ludwig
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; University of California, Los Angeles, Los Angeles, CA; Veterans Administration Puget Sound Health Care System, Seattle, WA; Virginia Mason Medical Center, Seattle, WA; ImClone Systems, New York, NY
| | - S. R. Plymate
- Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA; University of California, Los Angeles, Los Angeles, CA; Veterans Administration Puget Sound Health Care System, Seattle, WA; Virginia Mason Medical Center, Seattle, WA; ImClone Systems, New York, NY
| |
Collapse
|
9
|
Abstract
In this work, the stoichiometric metabolic network of Escherichia coli has been formulated as a comprehensive mathematical programming model, with a view to identifying the optimal redirection of metabolic fluxes so that the yield of particular metabolites is maximized. Computation and analysis has shown that the over-production of a given metabolite at various cell growth rates is only possible for a finite ordered set of metabolic structures which, in addition, are metabolite-specific. Each regime has distinct topological features, although the actual flux values differ. Application of the model to the production of 20 amino acids on four carbon sources (glucose, glycerol, lactate, and citrate) has also indicated that, for fixed cell composition, the maximum amino acid yield decreases linearly with increasing cell growth rate. However, when the cell composition varies with cell growth rate, the amino-acid yield varies in a nonlinear manner. Medium optimization studies have also demonstrated that, of the above substrates, glucose and glycerol are the most efficient from the energetic viewpoint. Finally, model predictions are analyzed in the light of experimental data.
Collapse
Affiliation(s)
- S M See
- Department of Chemical Engineering, University of Manchester, UK
| | | | | |
Collapse
|